Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis c virus infections uncover molecular determinants for E2 targeting and vaccine design by Keck, Zhen Yong et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Broadly neutralizing antibodies from an individual that naturally cleared multiple
hepatitis c virus infections uncover molecular determinants for E2 targeting and
vaccine design
Keck, Zhen Yong; Pierce, Brian G.; Lau, Patrick; Lu, Janine; Wang, Yong; Underwood,
Alexander; Bull, Rowena A.; Prentoe, Jannick; Velázquez-Moctezuma, Rodrigo; Walker,
Melanie R.; Luciani, Fabio; Guest, Johnathan D.; Fauvelle, Catherine; Baumert, Thomas F.;
Bukh, Jens; Lloyd, Andrew R.; Foung, Steven K.H.
Published in:
P L o S Pathogens
DOI:
10.1371/journal.ppat.1007772
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Keck, Z. Y., Pierce, B. G., Lau, P., Lu, J., Wang, Y., Underwood, A., ... Foung, S. K. H. (2019). Broadly
neutralizing antibodies from an individual that naturally cleared multiple hepatitis c virus infections uncover
molecular determinants for E2 targeting and vaccine design. P L o S Pathogens, 15(5), [e1007772].
https://doi.org/10.1371/journal.ppat.1007772
Download date: 03. Feb. 2020
RESEARCH ARTICLE
Broadly neutralizing antibodies from an
individual that naturally cleared multiple
hepatitis C virus infections uncover molecular
determinants for E2 targeting and vaccine
design
Zhen-Yong Keck1, Brian G. Pierce2,3, Patrick Lau1, Janine Lu1, Yong Wang1,
Alexander UnderwoodID4, Rowena A. BullID4, Jannick PrentoeID5, Rodrigo Vela´zquez-
MoctezumaID5, Melanie R. Walker4, Fabio Luciani4, Johnathan D. Guest2,3,
Catherine FauvelleID6,7, Thomas F. Baumert6,7,8, Jens BukhID5, Andrew R. Lloyd4, Steven
K. H. FoungID1*
1 Department of Pathology, Stanford University School of Medicine, Stanford, California, United States of
America, 2 University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, Maryland,
United States of America, 3 Department of Cell Biology and Molecular Genetics, University of Maryland,
College Park, Maryland, United States of America, 4 Viral Immunology Systems Program, The Kirby Institute
and School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia, 5 Copenhagen
Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital and Department of
Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark, 6 Inserm U1110, Institut de Recherche sur les Maladies et He´patiques, Strasbourg,
France, 7 Universite´ de Strasbourg, Strasbourg, France, 8 Pole He´pato-digestif, Institut Hospitalo-
Universitaire, Hopitaux Universitaires de Strasbourg, Strasbourg, France
* sfoung@stanford.edu
Abstract
Cumulative evidence supports a role for neutralizing antibodies contributing to spontaneous
viral clearance during acute hepatitis C virus (HCV) infection. Information on the timing and
specificity of the B cell response associated with clearance is crucial to inform vaccine
design. From an individual who cleared three sequential HCV infections with genotypes 1b,
1a and 3a strains, respectively, we employed peripheral B cells to isolate and characterize
neutralizing human monoclonal antibodies (HMAbs) to HCV after the genotype 1 infections.
The majority of isolated antibodies, designated as HMAbs 212, target conformational epi-
topes on the envelope glycoprotein E2 and bound broadly to genotype 1–6 E1E2 proteins.
Further, some of these antibodies showed neutralization potential against cultured genotype
1–6 viruses. Competition studies with defined broadly neutralizing HCV HMAbs to epitopes
in distinct clusters, designated antigenic domains B, C, D and E, revealed that the selected
HMAbs compete with B, C and D HMAbs, previously isolated from subjects with chronic
HCV infections. Epitope mapping studies revealed domain B and C specificity of these
HMAbs 212. Sequential serum samples from the studied subject inhibited the binding of
HMAbs 212 to autologous E2 and blocked a representative domain D HMAb. The specificity
of this antibody response appears similar to that observed during chronic infection, suggest-
ing that the timing and affinity maturation of the antibody response are the critical
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determinants in successful and repeated viral clearance. While additional studies should be
performed for individuals with clearance or persistence of HCV, our results define epitope
determinants for antibody E2 targeting with important implications for the development of a
B cell vaccine.
Author summary
Studies of hepatitis C virus (HCV) infected individuals spontaneously clearing acute
infections provide an opportunity to characterize the specificities of associated protec-
tive antibody responses. In an individual who resolved three separate HCV infections
with different HCV genotypes, the antibodies induced during these acute infection epi-
sodes were similar to those induced during chronic infection. Surprisingly, the earliest
detected antibodies were directed against conformational HCV epitopes on the enve-
lope glycoprotein E2 (including polyprotein residues 434–446) known to be targeted by
broadly neutralizing antibodies. Taken together, the key B-cell determinants in sponta-
neous clearance are the timing and affinity maturation of broadly neutralizing antibody
responses.
Introduction
Over 70 million people worldwide are infected with hepatitis C virus (HCV), with an annual
mortality of approximately 400,000 associated with liver failure and hepatocellular carcinoma
[1, 2]. Encouragingly for patients with chronic infections with HCV, advances in understand-
ing of HCV virology have led to the development of virus-specific direct acting antivirals
(DAAs) [3, 4]. However, the large majority of infected patients remain undiagnosed and/or
live in countries with limited resources and with minimal or no access to DAA-based thera-
pies. Indeed, global access to DAAs has been estimated to be less than 10% of HCV infected
individuals [5]. Thus, the prevention of global spread and eradication of HCV infection will
require a protective vaccine. A necessary step in the design of an effective vaccine is to identify
relevant mechanisms of immune protection. Vigorous and sustained CD4+ and CD8+ T cell
responses are associated with successful clearance, which occurs in 25% of acute infection epi-
sodes [6]. While humoral immunity has been traditionally thought to have a minor role in
controlling acute HCV infection, emerging evidence supports the importance of neutralizing
antibodies in spontaneous viral clearance. The induction of a neutralizing antibody response
in the acute phase of infection has been associated with clearance of infection in single source
outbreaks of acute HCV infection [7]. Further, control of acute infection has been associated
with the early appearance of neutralizing antibody responses [8]. Broad reactivity of these neu-
tralizing antibody responses appears to be associated with viral clearance. However, further
information is needed on the timing and specificity of the neutralizing antibody responses
associated with viral clearance during acute infection and reinfection, and better understand-
ing on how these responses differ from those found during chronic infection will inform vac-
cine design.
We have addressed these issues by characterizing a panel of human monoclonal antibodies
(HMAbs) isolated from peripheral B cells of an individual that sequentially cleared genotypes
1b and 1a HCV infections, as well as subsequently clearing a genotype 3a HCV infection. Neu-
tralizing HMAbs from B cells obtained after resolved infections with genotype 1b and 1a HCV
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strains demonstrated broad reactivity and targeted overlapping conformational epitopes in
highly immunogenic clusters that are similar to those that have been characterized from HCV
infected subjects during chronic infections. Interestingly, the earliest neutralizing antibodies
induced in this individual were directed against a region on the E2 glycoprotein (including res-
idues 434–446) that is likely to be of low immunogenicity but is highly conserved. The early
appearance of these antibodies suggests an important role in viral clearance. Overall, these
findings support that natural clearance of acute HCV infection is associated with broadly neu-
tralizing antibodies that are similar to those observed during chronic infection, and that key
determinants in spontaneous clearance are the timing and affinity maturation of this response.
Results
Studied subject
We studied an individual, designated as 300212, who had three documented episodes of acute
HCV infection acquired through injection drug use over a course of 320 weeks. Each episode
was associated with spontaneous clearance. Sequential samples of blood were obtained to iso-
late peripheral blood mononuclear cells (PBMCs) and serum. The subject was a 21-year-old,
immunocompetent male who screened negative for HIV, HBV and HCV antibodies before
enrollment in an ongoing prospective cohort study of high risk, uninfected injection drug
users—the Hepatitis C Incidence and Transmission Study in prisons (HITS-p). He was HCV
seropositive and RNA positive with a genotype 1b infection at 41 weeks after his initial evalua-
tion, and 21 weeks after his first estimated infection (midpoint between his last known HCV
antibody negative test and first antibody positive test) (S1 Table) [9]. The collection dates
described in this report are designated as the number of weeks after this first estimated date of
infection. He was also found to have the IL28B rs12979860 polymorphism associated with
spontaneous viral clearance [10]. On enrollment into HITS-p, he reported that he started
injecting drugs four years earlier. During regular follow-up in HITS-p, he reported periods of
daily injecting drug use and sharing of needles with other inmates. At week 76 post-infection
testing, he was HCV RNA negative, but remained HCV seropositive. At week 122, he became
transiently HCV RNA positive with a second infection, with a genotype 1a isolate. After only
one week of viremia, he became HCV RNA negative. This aviremic status persisted until week
277, when he was diagnosed with a third infection with a genotype 3a isolate. Viremia contin-
ued until week 303, but was not detected at week 320.
A broadly neutralizing antibody response was associated with viral
clearance
To assess whether neutralizing antibodies contributed to viral clearance of the first two epi-
sodes of acute HCV infection in the individual 300212, serum serial dilutions, 1:100, 1:500,
1:1000, 1:5000 and 1:10,000, at each timepoint from week 21 to 182 (except for week 161) were
tested for binding and neutralizing activities against the autologous 1b isolate and a heterolo-
gous 2a isolate (Table 1). Thus, an autologous genotype 1b HCVpp was constructed from the
first infection at week 21, termed 212 1b HCVpp. For the second and third infections, recovery
of autologous E1E2 was not successful. Serum antibody binding was determined against cell
lysates expressing 212 1b recombinant E1E2 by ELISA. To begin to assess breadth of neutrali-
zation, one other isolate was tested, JFH1 2a HCVcc. In the viremic phase of the first infection
at week 21, significant binding for serum antibodies to autologous E1E2 was only detected at
1:100 dilution (as defined by>0.5 optical density (O.D.)). However, no significant neutralizing
activities were present (defined by�50% neutralization, IC50) at this timepoint even at a
Protective antibodies against hepatitis C virus during acute infection
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reciprocal serum dilution of 100 (Table 1). By contrast at week 76, when the subject was not
viremic, peak antibody binding titer of 5000 was observed against 212 1b E1E2. Neutralizing
serum antibody titers of 500 and 1000 were observed, respectively, against autologous 212 1b
HCVpp and heterologous 2a HCVcc. The presence of neutralizing activity against a heterolo-
gous isolate is consistent with the induction of broadly reactive neutralizing antibodies. While
it is not known when in the weeks 21 and 76 interval that clearance occurred, a pattern of
increasing binding and neutralizing antibody titers was observed. To assess whether this
response at week 76 was directed against conformational epitopes on E1E2, serum antibody
binding studies were performed employing native and denatured antigens. As shown by signif-
icant reduction in antibody binding titers to denatured autologous 212 1b and heterologous
H77C 1a E1E2 antigens (Fig 1), the antibody responses were directed mainly at conforma-
tional epitopes. The subject did not have further follow-up until week 122, when a second
infection with a genotype 1a isolate was detected at a lower viral load than the first infection
(Table 1). Serum antibody binding titer at week 122 was reduced to 1000 against 212 1b, but
neutralization was maintained at 500 against this isolate. Seven days later at week 123, sponta-
neous viral clearance had occurred. An increase in neutralizing titer to 1000 was observed at
week 135 against 212 1b HCVpp. At weeks 150 and 182, neutralizing titers were 100 and 500
against 212 1b HCVpp and 2a HCVcc, respectively.
To further assess the breadth of neutralizing antibody responses, serum neutralization at
the same dilutions (with the addition of 1:50) from week 21 to 182 were tested against a panel
of 11 heterologous HCVpp (Fig 2 and S1–S4 Figs). Consistent with the findings against autolo-
gous 212 1b HCVpp and a heterologous 2a HCVcc (Table 1), no significant neutralizing activ-
ity (defined by�50% neutralization) against any heterologous HCVpp was observed for week
21, even at a reciprocal serum dilution of 50 (S1–S4 Figs). By week 76, all heterologous geno-
type 1 HCVpp (S1 Fig) were neutralized with a minimum neutralizing titer of 50 and similarly,
one of two genotype 2 HCVpp (S2 Fig), one of three genotype 3 HCVpp (S3 Fig), a single
genotype 5 and a single genotype 6 HCVpp (S4 Fig). The variants, e.g., UKN3A1.9 and
UKN4.11.1 (S3 and S4 Figs), that are poorly neutralized are likely escape/resistant isolates.
Taken together, these findings at week 76 provide further evidence for the induction of broadly
neutralizing antibodies (Fig 2). During the second infection (week 122), while cross-genotype
neutralizing titers had dropped, neutralizing titers against other genotype 1 isolates remained
at 50 or higher (Fig 2). Serum neutralizing titers after this timepoint decreased, except for the
two isolates H77.20 (1a) and UKN5.14.4 (5a), for which they remained unchanged even after
spontaneous viral clearance. Collectively, a pattern of no or low neutralizing activity at week
21 (initial viremia) that increased to higher neutralizing activity levels at week 76 against a
Table 1. Serum antibody reactivity and neutralization against autologous HCVpp and neutralization against a heterologous HCVcc.
Timepoint Genotype Specific Binding� Neutralization
Viral load (IU/ml) 212 1b� 212 1b HCVpp 2a HCVcc
21 1b 41802 100� <100�� <100
76 - 5000 500 1000
122 1a 746 1000 500 500
123 - 1000 500 500
135 - 1000 1000 500
150 - 1000 100 500
182 - 1000 100 500
�Serum binding titer in which relative optical density is >0.5 to recombinant E1E2 by ELISA. Tested in triplicates and the mean of two experiments.
��Serum neutralization titer in which 50% inhibition (IC50) is calculated from dose-dependent neutralization. Tested twice in triplicates; representative experiment shown.
https://doi.org/10.1371/journal.ppat.1007772.t001
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genotype-diverse panel of HCVpp is indicative of broadly neutralizing antibodies being
induced as part of the antibody response to the first infection. The second infection also was
associated with development of higher neutralizing titers against an autologous isolate (from
the first infection) temporally associated with viral clearance, observed at week 135 (Table 1).
Human monoclonal antibodies to HCV isolated during viral clearance
To characterize the specificity of the antibody response, week 123 was selected for investiga-
tion. This timepoint was one week after the detection of the second HCV infection with a
genotype 1a isolate at week 122, when viral RNA was no longer detected (Table 1). B cells iso-
lated from PBMCs were used to construct a yeast scFv displayed library [11]. Of 600 monoclo-
nal scFv cells that bound to E2, 27 having unique combinations of heavy and light chain
CDR1, 2 and 3 regions were identified and converted to full IgG1 molecules. Of note are that
two scFv clones, 212.1.1 and 212.9, accounted for more than 50% of the total clones analyzed.
HMAbs 212.1.1 to 212.1.4 have the same VH but different VL. Similarly, 212.2.1 and 212.2.2,
as well as 212.3.1 and 212.3.2, respectively have the same VH but different VL. Full-length
IgG1 converted HMAbs were initially analyzed for their neutralization against heterologous
H77C 1a HCVpp and JFH1 2a HCVcc, and autologous 212 1b HCVpp (Table 2). Fourteen of
27 E2 binding HMAbs neutralized at least one of two heterologous isolates, 1a H77C HCVpp
and 2a JFH1 HCVcc, or autologous 212 HCVpp by >40%. The remaining 13 E2 binding
HMAbs did not show significant neutralization activity. Among the 14 neutralizing antibodies,
five HMAbs neutralized all three isolates, four HMAbs neutralized two isolates and five
HMAbs neutralized one isolate. The last group of five antibodies neutralized only 2a JFH1
HCVcc, but not the autologous 212 HCVpp or heterologous 1a H77C HCVpp.
Fig 1. Serum antibodies from individual 300212 with acute resolving HCV infections are mainly to
conformational virus envelope determinants. Recombinant autologous 212 1b (square symbol) and H77C (circle
symbol) E1E2 lysates were either left untreated (native, solid symbols) or denatured (open symbols). After treatment,
the proteins were captured by pre-coated GNA wells. Bound proteins were incubated with week 76 serum diluted at
1:100, 500, 1000, 5000, and 10,000 (x-axis). Bound antibodies were detected as described in Materials and Methods.
The y-axis shows the mean optical density values for triplicate wells, the mean of two experiments ±SD.
https://doi.org/10.1371/journal.ppat.1007772.g001
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Broadly reactive HMAbs 212 are directed against conformational epitopes
Five HMAbs were selected for additional studies, 212.1.1, 212.9, 212.10, 212.15 and 212.25 that
represent the range in neutralization patterns (i.e. against all three isolates, or two with or with-
out the autologous isolate). Cross-reactivity of the HMAbs was examined against ten E1E2
proteins derived from six different HCV genotypes and subtypes (S2 Table). Broad binding
patterns were observed for all antibodies, except for 212.1.1 that bound to only three of ten iso-
lates. Two HMAbs, 212.10 and 212.25 bound to all ten isolates. Lower reactivity against geno-
type 3a was generally observed. Denaturation of 1b 212 E1E2 completely abrogated the
binding reactivity for all five HMAbs by ELISA, demonstrating that these antibodies are
directed against conformational epitopes on HCV E1E2 (Fig 3). As controls, HC33.1, an anti-
body directed to a predominantly linear epitope on the E2 glycoprotein, retained 80% binding
[12] and HC-11, an antibody to a conformational epitope on the E2 glycoprotein, lost more
than 95% binding to denatured E2 [13].
Identification of the 212.10 HMAb as a cross genotype 1–6 neutralizing
antibody
To further examine the cross-genotype neutralization potential of HMAbs 212, 212.1.1, 212.10
and 212.25 were tested in dose-response focus forming unit (FFU) reduction neutralization
assays [14] against an HCVcc genotype panel consisting of genotypes 1a (strains H77 and TN),
1b (J4 and DH1), 2a (J6), 2b (J8), 3a (S52 and DBN), 4a (ED43), 5a (SA13) and 6a (HK6a)
(Table 3) [4, 15–20]. No neutralization activity was observed for the negative control HMAb
Fig 2. Serum IC50 neutralization titers at different timepoints against heterologous genotype HCVpp in
individual 300212 with acute resolving HCV infections. Serum neutralization titers in which� 50% neutralization
was observed (IC50) against the 11 tested HCVpp were calculated using a non-linear regression analysis (Log inhibitor
vs normalized response) in GraphPad PRISM V7.02 (see S1–S4 Figs) and plotted longitudinally at defined time points
(x-axis). The viral load with the stated genotype isolates at these defined time points is plotted as the grey shading (left
y-axis).
https://doi.org/10.1371/journal.ppat.1007772.g002
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Fig 3. Selected HMAbs 212 do not bind to denatured autologous 212 1b HCV E2. Recombinant E1E2 lysate was
either left untreated (native, gray bars) or denatured (black bars). After treatment, the proteins were captured by pre-
coated GNA wells. Bound proteins were incubated with each 212 HMAb at 5 μg/ml (x-axis) and two control HMAbs,
HC33.1 and HC-11 [12, 53]. Bound antibody was detected as described in Materials and Methods. The y-axis shows
the mean optical density values for triplicate wells, the mean of two experiments ± SD.
https://doi.org/10.1371/journal.ppat.1007772.g003
Table 3. Neutralization activity of human monoclonal antibodies selected from individual 212 and controls
against HCVcc of genotypes 1–6.
Antibody
HCVcc (Core-NS2) genotype R04 212.1.1 212.10 212.25 HC84.27
H77 1a <15 41 (36) 50 (15) <15 97 (1.2)
H77ΔHVR1 1a <15 100 (0.0051) 100 (0.0017) 85 (3.4) 100 (0.00044)
TN 1a <15 53 (18) 84 (3.8) <15 91 (1.7)
DH1 1b <15 <15 48 (24) <15 48 (26)
J4 1b <15 <15 97 (0.90) <15 100 (0.34)
J6 2a <15 <15 25 (68) <15 44 (45)
J8 2b <15 <15 59 (2.5) <15 72 (2.3)
S52 3a <15 <15 <15 <15 54 (19)
DBN 3a <15 <15 95 (0.0083) <15 16 (57)
ED43 4a <15 40 (33) 79 (3.6) <15 100 (0.12)
SA13 5a <15 <15 94 (0.81) <15 25 (41)
HK6a 6a <15 26 (40) 99 (0.012) <15 100 (0.024)
The indicated HCVcc genotype recombinants were subjected to dose-response neutralization with the indicated
antibodies (S5–S8 Figs). Values represent % neutralization at 25 μg/ml. In the cases where the data permitted the
interpolation of IC50 values, these are given in parenthesis (in μg/ml). If more than 15%, but less than 50%,
neutralization was observed at 25 μg/ml, an additional neutralization was carried out at 75 μg/ml, permitting the
interpolation of an IC50 value by combining the data.
https://doi.org/10.1371/journal.ppat.1007772.t003
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R04 (targeting HCMV) against any of these HCVcc, whereas the positive control antibody
HC84.27 neutralized all tested HCVcc (S5–S8 Figs) [11]. Among the HMAbs 212, only 212.10
was cross-genotype reactive and neutralized all HCVcc strains tested except S52. Compared to
HC84.27, 212.10 was more effective against DBN and SA13, and less effective against H77, S52
and ED43. 212.1.1 neutralized HCVcc of genotypes 1a, 4a and 6a, whereas 212.25 did not neu-
tralize any of the tested HCVcc (S5–S8 Figs). We previously reported that lack of neutraliza-
tion against HCVcc could involve E2 hypervariable region 1 (HVR1) related antibody
protection [21–24]. We thus tested the HMAbs 212 against HCVcc H77 lacking HVR1 [25],
and found potent neutralization for 212.1.1 and 212.10, and neutralization potential for 212.25
(Table 3; S5 Fig); 212.25 had 670–7700 fold lower efficiency against H77ΔHVR1 than 212.1.1,
212.10 and HC84.27.
Competition with antigenic domain B to E antibodies
Broadly neutralizing HMAbs against HCV are predominantly directed against epitopes in E2
(reviewed in [26]) and epitope mapping and competition analysis has revealed that many of
these neutralizing antibodies are directed at overlapping epitopes, which can be grouped into
four distinct clusters, designated as antigenic domains B, C, D and E. Three of these clusters,
B, C and D, contain conformational epitopes, and E contains mainly linear epitopes on E2
[11–13, 27]. It should be noted that domains B and D antibodies are distinguished by their
respectively shared contact residues on E2. But some epitopes within domains B and D do
overlap with shared contact residues in the 441–443 region forming a domain B-D supersite of
conformational epitopes on the exposed surface of E2 [28]. The five 212 HMAbs initially
selected for further analysis were therefore examined for their reactivity to these antigenic
domains by competition studies with HMAbs HC-11 (domain B), CBH-7 (domain C),
HC84.27 (domain D) and HC33.1 (domain E) against autologous 212 1b recombinant E1E2
(S3 Table). HMAbs 212.1.1 and 212.10 blocked domains B, C and D HMAbs by >60%; HMAb
212.9 blocked mainly domains B and D; and HMAbs 212.15 and 212.25 blocked antigenic
domain C. There was no significant competition (defined as>40%) between these 212
HMAbs and HMAb HC33.1 (domain E). The findings place 212.15 and 212.25 epitopes within
domain C, and the remaining three, 212.1.1, 212.9 and 212.10, in domains B and/or D.
Neutralizing antibodies are present throughout the course of repeated
clearance associated with multiple HCV infections
To address the question regarding whether the HMAbs isolated from this individual are part
of a successful neutralizing antibody response, dilutions of sequential serum samples obtained
throughout the course of the first two infections were tested for the presence of these HMAbs.
Two antibodies, 212.1.1, and 212.15, were selected representing the antigenic domains B and
C-like antibodies that have been isolated. Serum samples from week 21 to 182 (S1 Table) were
diluted 1:100 to 1:10,000 and tested for their ability to block the binding of labeled 212.1.1 or
212.15 to recombinant 212 1b E1E2 (Fig 4A and 4B). No detectable inhibition was observed in
association with the first genotype 1b infection at week 21. Dose-dependent inhibition was
observed similarly with all subsequent serum samples, with some decrease against 212.15
HMAb at week 182. The patterns of domain B- and C-like antibodies being induced in
response to the first two infections are consistent with their role in viral clearance. It is also
possible that non-domain B- and C-like antibodies are induced that competed with 212.1.1 or
212.15.
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Global epitope mapping of 212 HMAbs
To definitively map the full set of E2 binding determinants of the HMAbs 212.1.1, 212.10,
212.15 and 212.25, we performed global alanine scanning of E2 with these four antibodies, in
addition to CBH-5, which is a previously described antigenic domain B HMAb (Fig 5A) [27].
Epitope mapping of HMAb 212.9 was not performed because this antibody did not bind to or
neutralize 1a H77C (S2 Table). After combining these measurements with results from our
previously mapped panel of 16 HMAbs, which target five antigenic domains on E2 [29], we
performed unsupervised clustering of this full set of antibodies (Fig 5B). This recapitulates ini-
tial assignment of HMAbs 212.15 and 212.25 as targeting antigenic domain C, while 212.1.1
and 212.10, in addition to CBH-5, are clustered with antibodies targeting the domain B-D
supersite. HMAb 212.1.1 diverges from 212.10 based on global binding data and is clustered
with antibodies targeting antigenic domain D, albeit with lower significance than the parent
Fig 4. Sequential serum inhibition of HMAb 212 binding to autologous 212 1b E2 and domains D and E HMAbs to 1a H77C E2. Recombinant 212 1b E2 (A and B)
or 1a H77C E2 (C and D) was captured by GNA in microtiter wells. The wells were then incubated with the indicated serum or normal serum control at dilutions of 100,
500, 1000, 5000 and 10000 for 30 minutes, followed by labeled HMAb 212.1.1 (A), 212.15 (B), HC84.27 (C) or HC33.1 (D) at 2 μg/ml. Binding was detected after anti-
human IgG-labeled horseradish peroxidase. The y-axis shows the mean optical density values for triplicate wells, the mean of two experiments ±SD.
https://doi.org/10.1371/journal.ppat.1007772.g004
Protective antibodies against hepatitis C virus during acute infection
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007772 May 17, 2019 10 / 28
Fig 5. Global alanine scanning of E2 glycoprotein binding determinants. (A) Individual E2 alanine mutants were
measured for binding affinity to four 212 HMAbs and HMAb CBH-5, which are shown along with 16 other HMAbs
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B-D supersite cluster (bootstrap probability 91%, versus 97% probability for the B-D
supersite).
To highlight shared and differential residue-level effects on antibody recognition, the four
212 HMAbs are compared with CBH-5 and other HMAbs for four segments on E2 (respec-
tively designated as regions 1, 2, 3, and 4 in Fig 6), including several key regions of E2 neutral-
izing antibody recognition. The antibody concentration used in epitope mapping was
optimized by a dose-dependent study employing 0.005–2 μg/ml against wt 1a H77C E1E2 and
a dose was chosen at 50% of maximum binding and in the linear portion of the binding curve,
212.1 at 2 μg/ml, 212.10 at 1 μg/ml, 212.15 at 0.5 μg/ml and 212.25 at 2 μg/ml (S9 Fig). Control
antibodies, HC-1, HC-11, CBH-5, HC84.26 and CBH-7 were at 1 μg/ml. 212.1.1 and 212.10
showed binding reduction patterns similar to HC-1 and HC-11, including two key domain B
contact residues at G530A and D535A [13]. The involvement of binding to residues within aa
529–540 is central to domain B, and these residues are also key for antibodies targeting E2
antigenic region 3 (AR3; HMAbs AR3A, AR3B, AR3C, AR3D), as shown by recent global epi-
tope mapping study [30]. The involvement of binding to 440–445 and without binding to aa
529–540 is central to domain D [11]. Thus, 212.1.1 and 212.10 HMAbs are within the domain
B cluster, though their mapping shows differential binding determinants, including residue
F442 where alanine substitution does not disrupt 212.1.1 binding but results in over 80% loss
of 212.10 binding. Notably, AR3 antibodies also lose binding when F442 is mutated to alanine
[30, 31], suggesting greater similarity to HC-11 and 212.10 than to HC-1 and 212.1.1. As
expected, these patient 212 antibodies blocked E2 interaction with CD81 (S10 Fig). Pre-incu-
bation of 1a H77C E2 glycoproteins with either 212.1.1 or 212.10 reduced E2 binding to CD81,
as observed with a control domain B antibody, HC-11. However, 212.9 is likely a domain B
antibody as evidenced by its ability to block HC-11 and 212.10 binding to autologous 1b E2
by> 60% (S11 Fig).
HMAbs 212.15 and 212.25 blocked mainly CBH-7, an antigenic domain C antibody (S3
Table). Epitope mapping confirmed that their epitopes have contact residues within aa 544–
549, as shown by greater than 60% reduction in binding to P544A, P547A and W549A (Fig 6).
These patterns are similar to CBH-7. In addition, both antibodies blocked E2 binding to CD81
(S10 Fig). However, 212.15 and 212.25 HMAbs have a critical binding determinant at residue
R639, which is not shared with CBH-7, but is shared with previously described antibody
AR5A that targets the E1E2 heterodimer [32]. Taken together, the neutralizing antibody
response in the individual 300212 during the acute phase of spontaneous clearance of a second
virus is directed mainly at two antigenic clusters, B and C.
Broadly neutralizing antibodies to epitopes encompassing aa 523–527 do
not impair HCV cell-to-cell transmission
Using an established experimental assay [33], we assessed whether HMAbs 212 impaired viral
cell-to-cell transmission in HCV Jc1-infected Huh7.5.1 cells. As shown in S12 Fig, the HMAbs
did not have a major inhibitory effect on cell-to-cell transmission of HCV Jc1 strain. It should
be noted that HMAb 212.10 neutralized the cell-free J6 HCVcc that is derived from the same
isolate as Jc1, while 212.1.1 could not neutralize cell-free J6 HCVcc (Table 3) [15, 34].
that were previously reported [29]. Affinities for each mutant are color coded based on percent binding with respect to
wild-type E2, and residues (rows) were clustered using hierarchical clustering in R (www.r-project.org). Asterisks
denote the HMAbs 212 and CBH-5, and antibody names are colored according to antigenic domains (A, red; B,
magenta; C, cyan; D, green; E, blue). (B) Clustering of HMAbs based on global alanine scanning. Numbers show
bootstrap confidence of clusters (out of 1.0), and clusters with bootstrap p-values greater than 0.95 are circled.
https://doi.org/10.1371/journal.ppat.1007772.g005
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HMAb germline and CDR sequences
To assess sequence features underlying the HMAbs 212 and antibodies targeting domains B
and C, germline genes, CDR3 amino acid sequence, and levels of somatic hypermutations
(SHMs) were compared with previously described domain B and C HMAbs (Table 4) [13, 35–
38]. HMAb 212 germline percent identities are at or above 89% for heavy chains variable
regions (Vh), and over 95% for light chain variable regions (Vl), in concordance with a previ-
ous study where broadly neutralizing antibodies from donors who spontaneously cleared
HCV were observed to have few SHMs [38] (one of those HMAbs, HEPC3, is included in
Table 2). One feature of the 212 and other domain B and C HMAbs in Table 4 is that all of
their heavy chains share the same germline gene, IGHV1-69, despite variability in CDR H3
sequence and length, and light chain germline genes. This preferential usage of IGHV1-69
gene in E2 HMAbs was noted previously [38–40] and may suggest a shared set of solutions for
targeting these conformational epitopes on E2, possibly facilitated by hydrophobic germline
Fig 6. Epitope mapping for HCV E2. Epitope mapping data for HMAbs 212, as well as other HMAbs for reference, are shown for four regions of E2: Region 1
encompassing aa 424–443, Region 2, aa 529–535, Region 3, aa 544–549, and Region 4, aa 636–639. Cells show binding percentage relative to wt, and are color
coded by percent binding as in Fig 5. Data are shown as mean values of two experiments performed in triplicate.
https://doi.org/10.1371/journal.ppat.1007772.g006
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residues in the CDR H2 loop which underlie IGHV1-69 gene usage in influenza hemagglutinin
stem antibodies [41].
Several of the domain B HMAbs also share a distinctive double-cysteine and double-glycine
motif (CxGGxC) in the context of CDR H3 loops ranging from 19 and 27 residues long. Addi-
tionally, in four out of five cases, this motif is preceded by a proline residue (i.e., PxxCxGGxC).
The precise cysteine-glycine organization of these HMAbs may be critical for antibody affinity
and neutralization; for the AR3C HMAb, which has been structurally characterized in complex
with E2, the cysteine residues form a disulfide bond, likely stabilizing the CDR H3 loop in a β-
hairpin conformation which makes numerous key hydrophobic contacts and hydrogen bonds
with E2 [42]. A search of the set of experimentally determined antibody structures in the PyIg-
Classify database [43] (June 2018 release) for other CDR H3 loops containing the CxGGxC
Table 4.
Heavy Light
HMAb Domain1 Vh %
ID2
CDR3 Vl %
ID2
CDR3 Reference3
HC-1 B 1–
69
90 AKVLQVGGNLVVRPL κ3–
20
93 HQYGNSPQT
HC-11 B 1–
69
92 AMEVPGFCRGGSCSGYMDV κ3–
20
96 QQYGSSPIT
AR3C B 1–
69
86 VRSVTPRYCGGGFCYGEFDY κ3–
15
95 QQYYRSPLT [36, 38]
AT12-
009
B 1–
69
87 VTSLSEPIPRSCRGGRCYSGPFDAFGV κ3–
15
94 QQYNNWPLT [37, 67]
AT12-
010
B 1–
69
92 GRDRAPRLCSGGRCHSPPDH κ1–
12
93 LQTNTFPYT [37, 67]
AT13-
021
B 1–
69
93 ARELIGYCTGGNCYSFGDF κ3–
15
97 HQYNTWPRG [37, 67]
CBH-5 B 1–
69
89 ARPHGDSSGIYRRPLDY κ1–
5
93 QYYNNFSGT
212.1.1 B 1–
69
93 AGVREGMAAISGKNAFDI κ3–
20
97 QQYNNWPPS
212.10 B 1–
69
89 ATDRMRDDSTLFRDSHFDN κ1–
39
98 QQSYSTPYT
HEPC3 B 1–
69
95 ARDGVRYCGGGRCYNWFDF κ1–
39
96 QQSHSTVRT [38, 57]
HEPC74 B 1–
69
92 ARDLLKYCGGGNCHSLLVDP κ1–
5
96 QHYNTYLFT [38, 57]
AT12-
011
C 1–
69
88 ARHDYFWGTPLDI κ6–
21
97 HQSYNLPRT [37, 67]
CBH-7 C 1–
69
92 ARRGYIYGSPFDY κ1–
39
96 QQSYSPLLT
212.15 C 1–
69
92 TRRSHYYGSGLDS κ1–
12
96 QQSYSTPYT
212.25 C 1–
69
93 ARGGDLYGSGPLYYYYGMDV κ3–
20
96 QQYDNLPPL
HC84.26 D 1–
69
91 ARGPLSRGYYDY λ3–
21
99 QVWDSSSVV
Heavy chain CDR3 cysteine residue pairs are highlighted in red.
1E2 antigenic domain targeted by the antibody, based on binding competition and epitope mapping.
2Percent nucleotide sequence identity to germline gene.
3Reference for antibody and sequence information, for HMAbs reported in other studies.
https://doi.org/10.1371/journal.ppat.1007772.t004
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motif identified two motif-containing CDRs out of 2172 unique CDR H3 sequences. These
correspond to the broadly neutralizing antibody F10 which targets the influenza hemaggluti-
nin stem and also includes the IGHV1-69 germline gene (PDB code 3FKU) [44], and the 8f9
antibody which binds a peptide antigen from human cytomegalovirus (PDB codes 3EYF,
3EYO) [45]. In both cases, intra-loop disulfide bonds are present, as with AR3C, suggesting
that this is a shared mechanism to stabilize CDR H3 loops, and that other domain B HMAbs
with this motif are likewise disulfide-stabilized, possibly in an AR3C-like β-hairpin
conformation.
Neutralizing antibody response to less immunogenic regions on HCV E2
A conserved region on E2, encompassing aa 412–423 (designated as antigenic domain E),
mediates broadly neutralizing antibodies to linear epitopes, but is known to be of lower immu-
nogenicity than other regions [12, 46]. An adjacent region, encompassing aa 434–446, is also
likely to be less immunogenic, participates in forming conformational epitopes (designated as
antigenic domain D) and mediates broad virus neutralization [11]. Although domain D anti-
bodies are directed against conformational epitopes, a significant number of these antibodies
also bind to a linear peptide encompassing aa 434–446 on E2. Thus, to assess whether the anti-
body response in individual 300212 included antibodies to domains D and E, sequential serum
samples from weeks 21 to 182 were tested in serial dilutions for binding to synthetic peptides
encompassing aa 410–425 and aa 434–446. Minimal reactivity was observed against aa 410–
425 with a significant dropoff in binding (>0.4 O.D.) after 1:1000 serum dilutions for the
tested timepoints (Table 5). Significantly stronger reactivities were observed against aa 434–
446 at multiple timepoints, weeks 76, 122 and 123, where >0.4 O.D. at 1:5000 or greater in
dilution (Table 6). Interestingly, binding by serum antibodies at week 21 to aa 434–446 was
observed. This finding was surprising in that antigenic domain B and C antibodies (e.g.
212.1.1 and 212.15, Fig 4A and 4B) were not present at this timepoint. To characterize more
definitively the antibody response to antigenic domain D and because these antibodies are to
conformational epitopes, the ability of sequential serum samples to block HMAbs to D and E
epitopes was tested (Fig 4C and 4D). As expected, no inhibition was observed against HC33.1
(a domain E HMAb [12]) but dose-dependent inhibition was observed against HC84.27 (a
domain D HMAb [11]). Maximum inhibition at 1:100 serum dilution against HC84.27 was
highest at week 76, which then persisted throughout the remaining of the course of clinical
observation (Fig 4C). In contrast to serum binding at 1:100 dilution to peptide aa 434–446 at
week 21 (Table 6), the serum at this timepoint did not inhibit HC84.27 (Fig 4C). It is possible
that this discrepancy is due to different assay formats having differential sensitivity to detect
the presence of domain D antibodies, with a direct binding assay being more sensitive, as
Table 5. Serum antibody binding to synthetic peptide aa410-425.
Serum Dilution O.D.
Timepoint 100 500 1000 5000 10000 >2
21 0.03 0.05 0.08 0.09 0.09 1–2
76 2.19 2.09 1.44 0.19 0.03 0.5–1
122 1.82 0.78 0.49 0.00 0.00 0.2–0.5
123 1.78 0.79 0.48 0.04 0.00
135 1.81 0.82 0.48 0.13 0.12
150 2.07 0.67 0.39 0.03 0.00
182 1.83 0.56 0.46 0.08 0.04
https://doi.org/10.1371/journal.ppat.1007772.t005
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shown in Table 6. It is also possible that peptide aa 434–446 is recognized by other antibodies
to mainly linear epitopes [47].
Viral isolate sequences
To determine the presence of any particular sequence features underlying elicitation of broadly
neutralizing antibodies and viral clearance, 212 1b and 212 3a E1E2 sequences were aligned
along with H77C and genotype 1a consensus reference sequences, with the latter sequence
obtained from the Los Alamos National Laboratory HCV database [48] (Fig 7). Inspection of
three regions that contain binding determinants of HMAbs 212 and domain B, C and D anti-
bodies did not show major sequence changes for the 212 sequences, in particular for the 212
1b sequence, which was present at a timepoint that would potentially influence selection and
maturation of 212 HMAbs. It is unclear whether specific variations (e.g. G440A) or combina-
tions thereof in the 212 1b sequence possess any features leading to antibody elicitation,
though further investigation of these and other viral sequences may provide avenues to opti-
mize E2 and E1E2-based vaccine immunogens.
Discussion
The majority of neutralizing antibodies against HCV are directed against the E2 envelope
glycoprotein, because E2 directly interacts with the HCV co-receptors, scavenger receptor
class B type 1 (SR-B1) [49] and the tetraspanin CD81 [50] during virus entry. There is recent
evidence that E1E2 heterodimers, and not E2 alone, interacts with a third co-receptor, the
tight junction protein Claudin-1 [51]. While effective neutralizing antibodies are directed at
the HVR1 on E2, this region is associated with mutations leading to rapid viral escape without
Table 6. Serum antibody binding to synthetic peptide aa434-446.
Serum Dilution
Timepoint 100 500 1000 5000 10000 O.D.
21 1.00 0.37 0.23 0.06 0.03 > 2
76 2.52 2.46 2.02 0.78 0.46 1–2
122 2.49 1.87 1.21 0.42 0.22 0.5–1
123 2.57 1.87 1.29 0.44 0.23 0.2–0.5
135 2.44 1.62 1.20 0.38 0.20
150 2.21 1.50 1.08 0.36 0.20
182 2.28 1.46 1.17 0.31 0.17
https://doi.org/10.1371/journal.ppat.1007772.t006
Fig 7. Sequences of viral isolates from individual 212. A multiple sequence alignment of E1E2 amino acid sequences
from single 212 1b and 3a clones was produced, with H77C and genotype 1 consensus for reference, using MAFFT
software [60]. The genotype 1 consensus protein sequence was downloaded as part of the 2014 reference sequence set
from the LANL HCV database [60]. Three regions including common determinants of domain B, D and C HMAbs,
corresponding to Regions 1–3 in Fig 6, are shown. "." denotes identical amino acid residue at that position compared
with the top sequence (H77C).
https://doi.org/10.1371/journal.ppat.1007772.g007
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compromising viral fitness [24, 28]. Based on the isolation and characterization of HCV
HMAbs from B cells of patients with chronic HCV infections, the majority of broadly neutral-
izing antibodies recognize conformational epitopes on E2 and inhibit E2 binding to CD81
[26]. Cross-competition analyses delineate at least four immunogenic clusters of overlapping
conformational epitopes with distinct properties [11, 27]. Non-neutralizing HMAbs fall within
one cluster, which is designated as antigenic domain A. It is probable that this cluster of con-
formational epitopes and other non-neutralizing determinants are highly immunogenic and
account for a substantial portion of the antibody response to E2 [52]. Neutralizing HMAbs
segregate into three clusters of conformational epitopes, antigenic domain B, C and D. A fifth
cluster of linear epitopes mediating neutralization, domain E, located at aa 412–423 on E2, has
been identified by both murine and human monoclonal antibodies (reviewed in [26]). As the
human antibodies isolated from chronically infected subjects co-existed with viremia, a mini-
mal role for neutralizing antibodies in viral clearance has been the conventional view. None-
theless, accumulated findings have now provided strong support for neutralizing antibodies
facilitating spontaneous viral clearance during acute infection [7, 8]. The question that has
been addressed in the current detailed study of the antibody response in an individual who
repeatedly cleared HCV infections of different genotypes is whether the specificity of the
response is similar or dissimilar to the response observed in individuals that developed chronic
infections. Our findings are in agreement with the recent report of other antibodies isolated
from individuals during acute HCV infections that spontaneously resolved infections. Their
isolated HMAbs were similar to those isolated during chronic infection [38].
Overall, the studied individual showed a pattern of cross-genotype reactive neutralizing
antibodies increasing in titers from the viremic phase to spontaneous clearance of the two first
HCV infections. This pattern is consistent with earlier studies on the timing of appearance of
broadly neutralizing antibodies response correlating with spontaneous viral clearance [7, 8].
However, the individual did get re-infected in spite of having a robust antibody response at
week 76 after the first documented infection (Table 1). Contributing to viral clearance are
most likely robust CD4+ and CD8+ T cell responses that were temporally observed in the stud-
ied individual during the primary and repeated infections (personal communication and man-
uscript in preparation, A. Lloyd). We believe that both cellular and humoral immunity
contributed to the repeated episodes of spontaneous clearance. As for the specificities of the
antibody responses, the first indication that these antibodies are directed to conformational
epitopes is based on the decrease in serum antibody binding against denatured autologous and
heterologous E1E2 recombinant proteins. Autologous and heterologous E2 proteins were
employed to isolate a panel of HMAbs. Of 14 antibodies that neutralized at least one of the
tested isolates, eight neutralized autologous 212 1b HCVpp and these eight also neutralized at
least one of the heterologous isolates. No neutralizing antibodies directed at HVR1 were iso-
lated. This is somewhat surprising since HVR1 is immunodominant. A likely contributing fac-
tor is that these antibodies were isolated from a B cell response associated with the second
infection with a different isolate, and we screened with autologous E2 from the first infection.
A second possible factor is that the subject reported long periods of at least daily injection drug
use and sharing of these injections with other users. It is possible that during the 24 months
from the initial infection (week 21) to the second infection (week 122), the subject had other
undocumented episodes of HCV infection. Thus, the profile of the antibody response at week
123 may reflect multiple exposures to HCV that are associated with repeated viral clearance.
This may also pertain to the interval from weeks 123 to 182, underpinning the high serum
antibody binding and neutralizing titers maintained during this period.
In the panel of HMAbs that were isolated, two antibodies, 212.1.1 and 212.9, accounted for
more than 50% of the total clones analyzed. These two antibodies and a third, 212.10, are
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within a highly immunogenic cluster, designated as domain B. Antibodies to overlapping epitopes
within this antigenic domain account for the majority of described broadly neutralizing antibodies
[26], and here we found that 212.10 indeed neutralized strains representing 8 subtypes of geno-
types 1–6. While many of these antibodies exhibit broad neutralization, they can be associated
with viral escape, with and without compromised viral fitness [53]. Both 212.1.1 and 212.10
appear to bind to overlapping epitopes involving aa 523–527, a region on E2 with a possible role
in cell-to-cell transmission [54]. However, no inhibition was observed with either antibody.
HMAb 212.15 and 212.25 represent antibodies to another cluster of overlapping epitopes, anti-
genic domain C [27]. Epitope mapping of these antibodies was similar to CBH-7 (a domain C
antibody) that was previously isolated from a chronically infected patient. Antibodies to both of B
and C domains remained at relatively stable titers from weeks 76–182, although somewhat higher
at week 76 (Fig 4A and 4B). The implication being that by week 76, optimal in vivo affinity matu-
ration of these antibodies had occurred, and there is no significant bias in the induction of anti-
bodies to these domains. Taken together, these results suggest that antigenic domain B and C
antibodies contributed to the protective immunity in this individual. While this immunity did not
prevent reinfection, it did potentially prevent progression to chronic infection. Additional studies
are required to determine whether these antibodies elicited during acute infection are associated
with viral escape, as demonstrated for other HMAbs [11, 25, 53, 55].
The studied individual with acute HCV infections also developed antibodies against anti-
genic domain D. Although domain D antibodies are directed to conformational epitopes,
some of these antibodies also bind to synthetic peptides encompassing aa 434–446 [11].
Sequential serum reactivity to this peptide and inhibition of the binding of a labelled domain
D HMAb to E2 indicate the presence of domain D-specific antibodies in these sera. Finding
antigenic domain D antibodies is unusual in that this region is of lower immunogenicity, as
indicated by the identification of HMAbs to this domain only after eliminating the detection
of antigenic domains A and B antibodies [11]. This domain is known to have highly conserved
overlapping epitopes and the associated antibodies have the broadest reactivity among diverse
HCV genotypes and subtypes, as compared to domains B and C antibodies. Not only are these
part of the antibody response in the individual reported here, but the antibodies may appear at
the earliest time point at week 21, as detected by direct serum antibody binding to aa 434–446,
when antibodies to antigenic domain B and C were not present. Although serum neutralizing
activity titers were less than 100 at this timepoint, the binding studies clearly indicated the
presence of domain D antibodies, albeit at low levels. One possible interpretation of these find-
ings is that protective B cell immunity is associated with the early induction of neutralizing
antibodies to antigenic domain D. To support this observation, other studies will be needed to
remove the possibility that aa 434–446 is recognized by non-domain D antibodies in this indi-
vidual. Additional studies will be required in other individuals that naturally cleared HCV
infections to confirm this observation on early induction of these protective antibodies. Inter-
estingly, the study subject carries the IL28B rs12979860 polymorphism that has been associated
with spontaneous viral clearance [10, 56] raising the suggestion that this innate immune
response genotype may be linked to development of effective neutralizing antibody responses.
The monoclonal antibodies described in this study underscore the importance of features
of the human antibody repertoire, including the IGHV1-69 germline gene, in targeting HCV
E2. Others recently isolated three IGHV1-69 HMAbs that target antigenic domain B (two of
these, HEPC3 and HEPC74, are noted in Table 4) from two individuals that spontaneously
cleared HCV [38], while intriguingly, a fourth HMAb described in the same study with the
IGHV1-69 germline gene had its binding mapped to residues in HVR1 [38]. Likewise, we
found that antigenic domain C, which is distinct from antigenic domain B [27], is targeted by
antibodies with the IGHV1-69 germline gene, including two HMAbs described here. Future
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studies can address the mechanistic and structural basis underlying the usage of this gene by
antibodies targeting these distinct sites. Interestingly, HMAbs HEPC3 and HEPC74 had their
structures determined in complex with E2, and the HMAb AR3A-E2 complex structure was
described in a separate recent study [40]; all feature disulfide-stabilized HCDR3 loops forming
critical interactions with antigenic domain B [57], in a similar manner as AR3C [36]. This sup-
ports the HCDR3 putative disulfide bond and common mode of E2 targeting for HC-11 and
other antigenic domain B HMAbs with the cysteine pair motif noted in Table 4.
Collectively, our results indicate that the development of a successful B cell vaccine will
require an understanding of the timing and affinity maturation of the humoral immune
response. In addition, there appears to be no advantages to study individuals with spontaneous
clearance as sources for B cells for the isolation of broadly neutralizing antibodies compared to
patients with chronic infection.
Materials and methods
Ethics statement
Human research ethics approvals were obtained from Human Research Ethics Committees of
Justice Health (reference number GEN 31/05), New South Wales Department of Corrective
Services (05/0884), and the University of New South Wales (05094, 08081), all located in Syd-
ney, Australia. Written informed consent was obtained from the adult participants.
Cell culture, antibodies, virus and reagents. HEK-293T cells were obtained from the
ATCC. The Huh7.5 cells, the 9E10 antibody and J6/JFH1 recombinant virus (HCVcc) were
generously provided by Dr. C. Rice (Rockefeller University). Dr. T. Wakita (National Institute
of Infectious Diseases, Japan) and Dr. J. K. Ball (University of Nottingham) generously pro-
vided respectively the 2a JFH1 HCVcc and a panel of genotype 1–6 E1E2 constructs. The
CD81 large extracellular loop fused to glutathione S-transferase was provided by Dr. S. Levy
(Stanford University). Anti-CD81 (JS-81) was from BD Biosciences (Heidelberg, Germany)
and anti-core C7-50 was from Abcam (Cambridge, UK).
Viral analysis. Qualitative HCV RNA detection was performed as described [58]. Viral
genotyping and testing for mixed infection was conducted as described [59]. The HCV geno-
type 1 E1 and E2 consensus protein sequences were downloaded from the LANL HCV data-
base (2014 genotype reference aligned sequences) [48], and E1E2 amino acid sequences were
aligned using MAFFT software [60].
Generation and selection of yeast display HCV-E2-scFv. The methods for generating
the yeast scFv displayed library, selection of HCV E2-specific scFv and production of scFvs
and IgG1 HMAbs have been described previously in details [11]. Selection was by a combina-
tion of employing 212 1b and H77C recombinant E2 proteins. Individual scFv clones reactive
to either E2 by flow analysis were sequenced; soluble scFv and full-length IgG1 were produced
and purified as described [11].
Neutralization assays (HCVcc and HCVpp). HCVcc neutralization was measured with a
modified version of an FFU assay as described previously [11]. Serial dilutions of HMAbs and
HCVcc (containing a volume of viral stock with a readout of approximately 3000 FFU) were
pre-incubated for 1h. The virus-HMAb mixture was added to Huh7.5 cell monolayers and
incubated for 3h. Fresh medium were added to the infected cells after washing and incubated
for 72h. Cells were then washed and lysed with lysis buffer in the presence of protease inhibi-
tors. Lysate was transferred to GNA-coated plate and incubated for 1h. Bound E2 was detected
by a HMAb to E2, CBH-5 [27], and detected by HRP conjugated anti-human IgG by ELISA, as
described below. The infectivity reduction was determined by the relative O.D. (450/570 nm)
in the presence and absence of antibody and was expressed as a percentage of neutralization.
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Production and neutralization of HCV retroviral pseudotype particles expressing E1E2
(HCVpp) were as described [61].
Testing of 212 HMAbs neutralization against Core-NS2 HCVcc virus panel. The panel
represented HCV strains of genotypes 1–6 [62]. We performed HCVcc neutralization as out-
lined in Springer Protocols [14]. We plated 7x103 Huh7.5 cell per well in poly-D-lysine 96-well
plates and incubated for 24 hours. Next day, a volume of virus stock corresponding to a read-
out of 20–200 FFU per well were incubated in quadruplicates with a dilution series of 212
monoclonal antibodies or relevant positive and negative control antibodies. Virus-antibody
mixes along with eight replicates of virus only were incubated for 1 hour at 37˚C, then added
to Huh7.5 cells and incubated for 4 hours at 37˚C and 5% CO2. Subsequently, the cells were
washed, and fresh medium was added prior to incubation for a total infection time of 48
hours. Cells were fixed and stained using 9E10 antibody as described previously [25], and the
number of FFUs were counted using an ImmunoSpot Series 5 UV Analyzer as described [63].
The data were normalized to 8 replicates of virus only and analyzed using four-parameter
curve fitting in GraphPad Prism 7.02. Virus stocks of all tested HCV recombinants had con-
firmed sequences of the encoded E1E2 envelope proteins.
Enzyme-linked immunoassays
a. Clinical HCV assays. HCV-specific antibody detection during the prospective study on
subject’s serum samples was conducted as described below for binding to native and denatured
E1E2 glycoprotein.
b. Serum competition assay. Serum samples at specified dilutions were tested for their
ability to block the binding of selected HCV HMAbs-conjugated with biotin in a GNA-cap-
tured E1E2 glycoproteins ELISA, as described [11].
c. Binding to native and denatured E1E2 glycoprotein. A standard ELISA was employed
to compare serum antibody or HMAb binding to native and denatured HCV E1E2 glycoproteins
as described [11]. Briefly, recombinant autologous 212 1b and H77C E1E2 lysates were either left
untreated or denatured by incubation with 0.5% sodium dodecyl sulfate and 5 mM dithiothreitol
for 15 min at 56˚C. After treatment, the proteins were diluted 1:5 in BLOTTO and captured by
pre-coated GNA wells. After washing and blocking, bound proteins were incubated with diluted
serum diluted or HMAb as indicated. Bound antibodies were detected as described.
d. Binding to a panel of genotype 1–6 E1E2 glycoproteins. A standard ELISA was
employed as outlined above for (c) binding to native E1E2 glycoprotein.
e. Blocking of E2 binding to CD81. Selected HMAbs at specified concentrations were
incubated for 20 min at 4˚C with recombinant E2. The HMAbs-E2 mixture was then added to
ELISA plates pre-coated with soluble CD81-LEL that were blocked with 2.5% BSA and 2.5%
normal goat serum in 0.1% Tween-PBS. Bound E2 was detected with biotinylated-CBH-4D, a
non-neutralizing HCV HMAb as described [27].
Epitope mapping. Epitope mapping was performed using alanine substitution mutants
by ELISA. Alanine substitution mutants were constructed as described [53] in plasmids carry-
ing the H77C E1E2 coding sequence (GenBank accession no. AF011751.1). The mutated con-
structs were designated X#Y, where # is the residue location in H77C, X denotes the single-
letter code for the H77C amino acid, and Y denotes the altered amino acid.
HCV cell-cell transmission assay. The effect of antibodies on HCV cell-to-cell transmis-
sion was assessed as described [33].
Clustering. Hierarchical clustering of alanine scanning data was performed as previously de-
scribed [29] using R (http://www.R-project.org/), after transforming binding percentage data to log
ratios, with binding values of 0% set to 0.5% to permit log calculation. E2 positions and antibodies
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were compared using Euclidean and correlation-based distances, respectively, and clustered using
Ward’s minimum variance method. Positions that lacked binding data for one or more HMAbs
were removed prior to clustering. Cluster p-values were computed using the approximate unbiased
method in the pvclust R package [64], with 10,000 bootstrap replicates. The unrooted tree was gen-
erated using the Analyses of Phylogenetics and Evolution (APE) package [65] in R.
Antibody sequence analysis. Antibody nucleotide sequences were analyzed using IMGT/
V-QUEST web server [66] to determine percent identity to Vh and Vl germline genes.
Study approval. All protocols were approved by the Institutional Review Board of Stan-
ford University. Ethical approvals were obtained from Human Research Ethics Committees of
Justice Health (reference number GEN 31/05), the New South Wales Department of Correc-
tive Services (reference number 05/0884), and the University of New South Wales (reference
numbers 05094, 08081, 13237, 09075, 14170), and written informed consent was obtained
from the study adult participant.
Supporting information
S1 Fig. Individual 212 serum neutralization titers against heterologous genotype 1
HCVpp. The % neutralization (y-axis) was plotted against the log10 serum dilution (x-axis)
for all defined time points listed in the figure legends. A non-linear regression analysis (log
inhibitor vs normalized response) was performed in GraphPad PRISM v7.02 to calculate the
estimated inhibitory concentration required to neutralize 50% of the virus (IC50). The % neu-
tralization was calculated by comparing the RLU of healthy serum to the RLU of the tested
serum (1-[RLU test serum]/[RLU healthy serum]).
(PDF)
S2 Fig. Individual 212 serum neutralization titers against heterologous genotype 2
HCVpp. The % neutralization (y-axis) was plotted against the log10 serum dilution (x-axis)
for all defined time points listed in the figure legends. A non-linear regression analysis (log
inhibitor vs normalized response) was performed in GraphPad PRISM v7.02 to calculate the
estimated inhibitory concentration required to neutralize 50% of the virus (IC50). The % neu-
tralization was calculated by comparing the RLU of healthy serum to the RLU of the tested
serum (1-[RLU test serum]/[RLU healthy serum]).
(PDF)
S3 Fig. Individual 212 serum neutralization titers against heterologous genotype 3
HCVpp. The % neutralization (y-axis) was plotted against the log10 serum dilution (x-axis)
for all defined time points listed in the figure legends. A non-linear regression analysis (log
inhibitor vs normalized response) was performed in GraphPad PRISM v7.02 to calculate the
estimated inhibitory concentration required to neutralize 50% of the virus (IC50). The % neu-
tralization was calculated by comparing the RLU of healthy serum to the RLU of the tested
serum (1-[RLU test serum]/[RLU healthy serum]).
(PDF)
S4 Fig. Individual 212 serum neutralization titers against heterologous genotypes 4–6
HCVpp. The % neutralization (y-axis) was plotted against the log10 serum dilution (x-axis)
for all defined time points listed in the figure legends. A non-linear regression analysis (log
inhibitor vs normalized response) was performed in GraphPad PRISM v7.02 to calculate the
estimated inhibitory concentration required to neutralize 50% of the virus (IC50). The % neu-
tralization was calculated by comparing the RLU of healthy serum to the RLU of the tested
serum (1-[RLU test serum]/[RLU healthy serum]).
(PDF)
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S5 Fig. Neutralization of HCVcc recombinants with Core-NS2 from genotype 1 HCV iso-
lates. Virus stocks of the indicated genotypes 1a and 1b HCV Core-NS2 recombinants were
subjected to dose-response FFU reduction neutralization assays using dilution series of the
antibodies (A) 212.1.1, (B) 212.10, (C) 212.25, (D) R04, or (E) HC84.27 in quadruplicates with
8 wells of virus only. Following a total of 48 hours infection the cells were immuno-stained
and the number of FFUs per well were counted as described in Materials and Methods. Error
bars represent standard error of the mean of four replicates normalized to 8 replicates of virus
only. The data was analyzed using four-parameter curve-fitting to obtain a sigmoidal dose-
response curve, permitting the interpolation of an IC50 value (Graphpad PRISM 7.02). J4 and
H77ΔHVR1 gave fewer than 20 FFUs/well in virus only wells against all antibodies.
(PDF)
S6 Fig. Neutralization of HCVcc recombinants with Core-NS2 from genotype 2 HCV iso-
lates. Virus stocks of the indicated genotypes 2a and 2b HCV Core-NS2 recombinants were
subjected to dose-response FFU reduction neutralization assays using dilution series of the
antibodies (A) 212.1.1, (B) 212.10, (C) 212.25, (D) R04, or (E) HC84.27 in quadruplicates with
8 wells of virus only. Following a total of 48 hours infection the cells were immuno-stained
and the number of FFUs per well were counted as described in Materials and Methods. Error
bars represent standard error of the mean of four replicates normalized to 8 replicates of virus
only. The data was analyzed using four-parameter curve-fitting to obtain a sigmoidal dose-
response curve, permitting the interpolation of an IC50 value (Graphpad PRISM 7.02).
(PDF)
S7 Fig. Neutralization of HCVcc recombinants with Core-NS2 from genotype 3 HCV iso-
lates. Virus stocks of the indicated genotype 3a HCV Core-NS2 recombinants were subjected
to dose-response FFU reduction neutralization assays using dilution series of the antibodies
(A) 212.1.1, (B) 212.10, (C) 212.25, (D) R04, or (E) HC84.27 in quadruplicates with 8 wells of
virus only. Following a total of 48 hours infection the cells were immuno-stained and the num-
ber of FFUs per well were counted as described in Materials and Methods. Error bars represent
standard error of the mean of four replicates normalized to 8 replicates of virus only. The data
was analyzed using four-parameter curve-fitting to obtain a sigmoidal dose-response curve,
permitting the interpolation of an IC50 value (Graphpad PRISM 7.02).
(PDF)
S8 Fig. Neutralization of HCVcc recombinants with Core-NS2 from HCV isolates of geno-
types 4–6. Virus stocks of the indicated genotypes 4a, 5a, or 6a HCV Core-NS2 recombinants
were subjected to dose-response FFU reduction neutralization assays using dilution series of the
antibodies (A) 212.1.1, (B) 212.10, (C) 212.25, (D) R04, or (E) HC84.27 in quadruplicates with 8
wells of virus only. Following a total of 48 hours infection the cells were immuno-stained and the
number of FFUs per well were counted as described in Materials and Methods. Error bars repre-
sent standard error of the mean of four replicates normalized to 8 replicates of virus only. The
data was analyzed using four-parameter curve-fitting to obtain a sigmoidal dose-response curve,
permitting the interpolation of an IC50 value (Graphpad PRISM 7.02). ED43 gave fewer than 20
FFUs/well in virus only wells against 212.10 and 212.25 and SA13 gave more than 200 (but no
more than 210) FFUs/well in virus only wells against 212.1.1, R04, and HC84.27.
(PDF)
S9 Fig. Dose-dependent binding of HMAbs 212 to H77C E1E2. Recombinant H77C 1a
E1E2 lysates were captured by pre-coated GNA wells. After washing and blocking, bound pro-
teins were incubated with each indicated 212 HMAb at 0.005–2 μg/ml (x-axis) for 30 minutes.
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After washing, bound antibodies were detected as described in Materials and Methods. The y-
axis shows the mean optical density values for triplicate wells, the mean of two
experiments ± SD.
(PDF)
S10 Fig. Inhibition of E2 binding to CD81-LEL by HMAbs 212. H77C 1a recombinant E1E2
lysate containing 1 μg/ml E2 was incubated with each test HMAb at 10 μg/ml. The antibody-
antigen complex was then added onto CD81-LEL-precoated wells. Detection of E2 bound to
CD81-LEL was measured with biotinylated CBH-4D [13, 35–38]. HC-11 was used as a positive
control and R04 as a negative control (a HMAb to HCMV). Inhibition of binding is expressed
as percent inhibition (y-axis). Experiments were performed twice in triplicate. Error bars indi-
cate one standard deviation from the mean.
(PDF)
S11 Fig. HMAb 212.9 is against an epitope within antigenic domain B. Recombinant autol-
ogous 1b E1E2 lysates were captured by pre-coated GNA wells. After washing and blocking,
bound proteins were incubated with each indicated 212 blocking antibody at 20 μg/ml (x-
axis), a control antigenic domain B HMAb, HC-11, and a no antibody control for 30 minutes.
After washing, labeled 212.9 HMAb at 2 μg/ml was added. Bound 212. 9 HMAb was detected
as described in Materials and Methods. The y-axis shows the percent competition by each
blocking antibody, the mean of two experiments ±SD that were performed in triplicates.
(PDF)
S12 Fig. HMAbs 212 do not inhibit cell-cell transmission. (A) Approach of HCV cell-cell
transmission experiments. HCV Huh7.5.1 producer cells cultured with naïve Huh7.5-GFP tar-
get cells were incubated with control or anti-HCV HMAbs (100 μg/ml) in the presence of anti-
HCV IgG (50 μg/ml) to block cell-free transmission similar as described [33]. Cell-to-cell
transmission was determined by quantification of HCV+ GFP+ target cells using immunos-
taining and flow cytometry. (B) HCV cell-cell transmission indicated as percentage of HCV-
infected Huh7.5-GFP target cells is shown as histogram. Means +/- SD from two independent
experiments performed in duplicate are shown. Incubation of cells with anti-CD81 MAb
served as positive control.
(PDF)
S1 Table. Chronology of multiple HCV infections. HCV RNA was detected as described in
Materials and Methods.
(PDF)
S2 Table. Antibody binding to different HCV genotypes and autologous isolates. A stan-
dard ELISA against of native E1E2 glycoproteins was performed as described in Materials and
Methods.
(PDF)
S3 Table. Competition of 212 antibody binding to E2. This study was performed as
described in Materials and Methods.
(PDF)
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